Analysis & Insights
Global Supply and Demand: The future of the antivirals landscape
Lead Analyst and Head of Therapeutics, Dr Arsalan Azad, hosts an exclusive session on antiviral supply and demand, sharing Airfinity’s independent analysis and forecasts on the treatment landscape.
The EconomistUK prepares to include over-50s in autumn Covid booster campaign
Financial TimesWHO to share vaccines to stop monkeypox amid inequity fears
Associated PressWaiving intellectual property rights is a flawed solution to achieving Covid-19 vaccine equity
STATAirfinity live on stage at FT US Pharma and Biotech Summit 2022
FT LiveView All →
Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.
Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.
All information that impacts the future of a therapy is collected, structured and analysed in near real time and provides you with probabilistic tools to inform the big decision.
Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Influenza and RSV.
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”
“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”
James Fransham, Data Journalist,